Bill Martin | Vice President, Pharma Strategy and Account Management
Express Scripts and Accredo

Bill Martin, Vice President, Pharma Strategy and Account Management, Express Scripts and Accredo

Bill Martin is the Chief Commercial Officer for Accredo. In this role, Mr. Martin is responsible for
guiding the development and growth of the organizations overall specialty business with payers,
pharmaceutical manufacturers, and distribution partners. He leads a team that is heavily focused on
growth through strategic initiatives, innovative clinical programs, and market development efforts.
Mr. Martin previously served as Vice President of Business Development and Strategy for Accredo
and has more than 25 years of experience within the healthcare industry. Mr. Martin has held
various positions of leadership including general management, marketing, medical education, sales,
and product development. His extensive industry experience includes pharmaceuticals, biologics,
medical devices, transplants, clinical trials, and distribution network management.
His key areas of interest include working with clients to maximize the value of their pharmacy and
medical benefits, as well as helping manufacturers to navigate the very complex and confusing
waters of the specialty marketplace. Mr. Martin holds a bachelor’s degree in Communications and
Business from The University of Tennessee.

Appearances:



Pharma Pricing & Market Access USA Day 1 @ 15:10

PANEL: Accelerated Approval and Expensive Drugs — A Challenging Combination

  • Despite the uncertain evidence of clinical benefit, drugs receiving accelerated approval enter the market as FDA-approved products. Insurers must decide whether and how to pay for them
  • How do insurers decide whether to pay for these drugs in light of little evidence?
  • Ensuring that confirmatory trials conducted after receiving accelerated approval are performed in a timely fashion and are designed optimally to limit the period of uncertainty about true clinical effect

Pharma Pricing & Market Access USA Day 1 @ 16:10

PANEL: The impact of precision medicine and biomarkers on drug pricing structures

  • Understanding how biomarkers will have an increasing role to play in drug pricing 
  • What impact will precision medicine have on the overall cost of healthcare
  • Do we have the necessary evidence to put a price on precision medicine?

back to speakers